First patient enrolled in Isofol’s Pivotal Phase 3 AGENT study in 1st line metastatic colorectal cancer
GOTHENBURG, Sweden, December 18, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first…
Privacy & Cookies Policy
These cookies are necessary for the website to function properly. These cookies ensure basic functionalities and security features of the website. These cookies do not store any personally identifiable information.